How Marijuana Affects Top Performers | Dorian Yates & Dr. Andrew Huberman

ELI5/TLDR

Six-time Mr. Olympia Dorian Yates has smoked cannabis daily for 30 years and claims it never dented his drive — in fact, he thinks it helped. Huberman mostly listens. The interesting thread: your endocannabinoid system varies genetically, which means cannabis affects different people in fundamentally different ways. The lazy stoner stereotype may say more about the person than the plant.

Summary

This is a conversation between Andrew Huberman and Dorian Yates — one of bodybuilding’s most dominant champions — about cannabis use in high performers. Yates, a daily smoker for three decades, makes the case that cannabis has substantial health benefits that have been suppressed by a century of propaganda and pharmaceutical industry interests. He cites a 25-year UCLA lung study (Dr. Donald Tashkin), Rick Simpson’s cannabis oil cancer work, and Dr. Sanchez’s research at the University of Madrid showing THC destroying cancer cells in vitro. Huberman stays in listening mode, occasionally noting cannabis’s established role in treating glaucoma and drawing parallels to how breathwork research was once dismissed as counterculture nonsense. The most substantive point: endocannabinoid system variability can now be tested via genetic swab, and this variation likely explains why cannabis is a performance tool for some and a paranoia machine for others.

Key Takeaways

• The Tashkin study (UCLA, 25-year longitudinal): Cannabis smokers showed no increase in lung cancer and a slight increase in lung capacity vs. non-smokers. Airway irritation was the main negative finding. Huberman was unfamiliar with this study — which is notable given its relevance to his platform.
• Endocannabinoid system genetic testing: Swab-based tests now exist that score your likelihood of negative cannabis effects on a 1-10 scale. Yates scored 1/10. His wife gets paranoid from small amounts. Same household, different biology.
• The amotivation question: Huberman’s “dime store psychologist theory” — cannabis may help already-driven people regulate, but amplify laziness in the unmotivated. Yates agrees: “If you’re lazy, you’re lazy.”
• Elite athlete usage: Yates claims 70-80% of NFL and NBA players use cannabis daily, citing recovery and performance benefits. His logic on team owners not intervening is worth considering.
• THC/CBD ratio problem: Modern breeding has pushed THC levels up while CBD has dropped, breaking the natural balance that made the plant more tolerable. This partly explains why contemporary cannabis causes more anxiety and paranoia than older strains.
• Historical context: Cannabis was an over-the-counter medicine in the US until the early 1900s. Queen Victoria used it for menstrual pain. The shift to prohibition was driven by pharmaceutical industry competition and racially motivated propaganda (Reefer Madness era).

Detailed Notes

The Lung Study That Challenges Assumptions

Yates references Dr. Donald Tashkin’s 25-year study at UCLA — three cohorts: cigarette smokers, cannabis smokers, and controls. The cigarette results were predictable. The cannabis results were not: no lung cancer, no loss of lung function, and a marginal increase in lung capacity. The only measurable negative was reduced antioxidant protection on airway surfaces, translating to slightly higher susceptibility to bronchitis. Yates points out that Peter Attia, in a previous Huberman appearance, apparently equated cannabis smoke with tobacco smoke — a claim this study directly contradicts. Huberman admits he hasn’t seen the study, which is a reasonably significant gap for someone running the internet’s most prominent health science podcast.

Cannabis, Cancer, and Rick Simpson Oil

The Rick Simpson thread: a Canadian farmer who stumbled onto cannabis oil’s effect on his own skin cancer, then spent years producing and giving away RSO (Rick Simpson Oil) for free before being prosecuted by Canadian authorities. He now lives in Europe. Yates also cites Dr. Cristina Sanchez at the University of Madrid, whose lab work shows THC-induced apoptosis in cancer cells on video. Huberman confirms he’s seen this research. The conversation frames these as promising but still-emerging areas that institutional resistance has kept from mainstream adoption.

The Endocannabinoid System as Individual Fingerprint

The most scientifically interesting claim: genetic swab tests can now profile your endocannabinoid system and predict your response to cannabis. Yates tested in Spain and scored a 1 out of 10 for likelihood of negative effects. His wife, by contrast, experiences paranoia from even small doses. This framing moves the conversation past the tired “cannabis good vs. bad” binary into something more useful — individual pharmacogenomics applied to cannabinoids.

The Motivation Question

Huberman raises the stereotype head-on: many heavy cannabis users he knows became amotivated. But Yates was winning Mr. Olympia titles while smoking daily. Huberman’s working theory: cannabis as a regulatory tool works for people who are already running too hot. For people who lack drive, it removes what little friction was keeping them moving. Yates doesn’t disagree, but reframes it — the plant doesn’t create laziness, it reveals it.

Prohibition as Pharmaceutical Market Protection

Yates gives the potted history: cannabis was available as medicine in the US in 1900, Queen Victoria used it therapeutically, and the shift to prohibition was commercially and racially motivated. The Reefer Madness propaganda era explicitly linked cannabis use by white women to sexual relationships with Black men. He argues the current negative perception is a residue of this campaign rather than evidence-based medicine.

The Modern Strain Problem

A useful practical point: selective breeding has pushed THC concentrations far above historical norms while CBD levels have dropped. Since CBD modulates THC’s psychoactive effects — functioning as a kind of neurochemical seatbelt — the modern high-THC, low-CBD flower is a meaningfully different substance than what existed a few decades ago. This partly explains the increase in cannabis-related anxiety and psychotic episodes.

Quotes/Notable Moments

“If you’re lazy, you’re lazy, right? Maybe it just amplifies it.” — Dorian Yates, delivering what might be the most concise rebuttal to the amotivational syndrome hypothesis

“You know, they did a survey with the NFL players and NBA players. How many of them use cannabis on a daily basis — in between 70 and 80%. So, we’re talking about the most elite athletes in the world, highest paid athletes. They wouldn’t be doing that if it wasn’t benefiting them.” — Yates, deploying the revealed-preferences argument

“20 years ago if you said breath work people were like okay where’s your magic carpet and there’s the door and let’s lock you out.” — Huberman on how quickly the Overton window moves in health science

“What does it say there? Do I need THC for life?” … “Well, you’re not far off.” — Yates recounting his endocannabinoid system test results with the kind of satisfaction that suggests he already knew the answer

Claude’s Take

This is an interesting conversation that lands somewhere between genuinely informative and advocacy dressed as science. A few things to flag:

What’s solid:

• The Tashkin study at UCLA is real and its findings are as Yates describes them, though the “slight increase in lung capacity” is likely attributable to the deep inhalation technique of cannabis smoking rather than any therapeutic property of the smoke itself. The no-cancer finding is genuinely significant and under-discussed.
• Cannabis for glaucoma is well-established. Huberman is on firm ground here.
• The endocannabinoid system variability claim is directionally correct. Pharmacogenomic testing for cannabinoid response is an emerging field, though its clinical validity is still being established.
• The THC/CBD ratio shift in modern strains is a real and important public health observation.

What’s speculative or overstated:

• The Rick Simpson Oil cancer cure claims are anecdotal and not supported by clinical trials. In vitro studies (cells in a dish) showing THC-induced apoptosis do not translate to “curing hundreds of people with cancers.” This is the oldest misinterpretation in oncology — killing cancer cells in a petri dish is easy; bleach does it too. The clinical evidence gap here is enormous, and Yates presents it as essentially settled.
• The 70-80% NFL/NBA daily cannabis use claim is unverifiable and likely inflated. Anonymous player surveys have suggested high usage rates, but “daily basis” at those percentages would be extraordinary. The logic that “owners would stop it if it didn’t help” also doesn’t hold — owners care about game-day performance, not whether players are optimizing their recovery protocols.
• Yates’s personal experience (driven guy, smokes daily, still productive) is a sample size of one. Survivorship bias is doing heavy lifting throughout this conversation.

The broader picture: Huberman is notably deferential here — more so than usual. He doesn’t push back on any of the more aggressive claims, admits unfamiliarity with key studies Yates cites, and mostly validates. This is fine as an interview strategy but means the conversation lacks the adversarial pressure that would distinguish strong claims from weak ones. The most valuable contribution is actually the framing around individual variation in the endocannabinoid system, which correctly shifts the discourse from “is cannabis good or bad” to “good or bad for whom, and can we test for it.” That question is worth more than anything else discussed here.